SCHEMBL29080161

SCHEMBL29080161

CC(C)(Cc1cc(O)cc2ccc(F)c(Cl)c12)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBXA2R P21731 1/20 0.37
▸ PTGES2 Q9H7Z7 7/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ ESR1 P03372 2/20 0.35
▸ ESR2 Q92731 2/20 0.35
▸ PTGES O14684 5/20 0.34
▸ ALOX5AP P20292 2/20 0.33
▸ AKR1C3 P42330 1/20 0.33
▸ AKR1C2 P52895 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24680259 0.81 ESR1 (0.48) MAPTTSHRESR1ESR2
SCHEMBL29080067 0.80 PPARA (0.34) TBXA2RPTGES2KDM4ECYP2C9HSD17B10
SCHEMBL26058906 0.72 ESR1 (0.38) TBXA2RKDM4ECYP2C9HSD17B10CYP1A2
SCHEMBL29080200 0.71 ELANE (0.38) CYP3A4HIF1AESR1ESR2LMNA
SCHEMBL24663180 0.70 CYP3A4 (0.47) TBXA2RCYP3A4ESR1ESR2
SCHEMBL24535006 0.69 ESR1 (0.46) ESR1ESR2
SCHEMBL24176030 0.67 GABRA1 (0.40) TBXA2RCYP3A4ESR1ESR2LMNA
SCHEMBL31609498 0.67 ESR1 (0.39) TBXA2RCYP3A4ESR1ESR2
SCHEMBL26059134 0.67 ESR1 (0.39) TBXA2RCYP3A4ESR1ESR2
SCHEMBL26060359 0.67 ESR1 (0.49) KDM4EHSD17B10MAPTESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116829151-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2023-09-29 — — CN disclosed
Send feedback